Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine
- Development stage
- Phase 1
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
A patient-specific cancer DNA vaccine designed for the treatment of B-cell lymphomas such as lymphoplasmacytic lymphoma. The vaccine is created by isolating the variable regions (VH and VL) of the immunoglobulin from a patient's own tumor cells, constructing a single-chain variable fragment (scFv), and fusing it to the human chemokine CCL20 (macrophage inflammatory protein 3 alpha, MIP-3α). This fusion gene is then inserted into a plasmid vector to create a personalized DNA vaccine. Upon intradermal administration, the encoded fusion protein targets antigen-presenting cells expressing CCR6 via CCL20-mediated chemotaxis and presents tumor-specific idiotype antigens to stimulate an anti-tumor immune response[1][2][7]. The approach aims to enhance dendritic cell uptake and presentation of tumor antigens, thereby inducing both humoral and cellular immunity against residual or relapsing lymphoma.
- Other names
- autologous lymphoma scFv-human CCL20 (MIP-3α) fusion protein DNA vaccinepatient-specific idiotype chemokine fusion DNA vaccine
02
Targets
CCR6 (C-C motif chemokine receptor 6)Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine.